Psyence Biomedical Ltd

Psyence Biomedical Ltd is a pioneering pharmaceutical life science biotechnology company, traded on the NASDAQ (NASDAQ:PBM), with a strong focus on botanical psychedelics. As the first NASDAQ-listed nature-derived psilocybin biopharma in the world, Psyence Biomed is committed to an evidence-based approach to innovative biopharmaceutical solutions. The company's dedication is reflected in its name, which combines "psychedelics" and "science."

Patient-centered and physician-led, Psyence Biomedical Ltd is actively developing an FDA-approved pharmaceutical botanical psilocybin. This innovative treatment aims to address psychosocial distress in oncology patients diagnosed with Adjustment Disorder within a palliative care context. The company's commitment to research and development is underscored by its ongoing Phase IIb trials, which have received ethics approval and are commencing patient enrollment this quarter.

With its headquarters in Toronto, CA, Psyence Biomedical Ltd is poised to make significant contributions to the field of palliative care and mental health. We invite the management of Psyence Biomedical Ltd to create a customized and exclusive company showcase and product listing on our platform to further amplify your reach and impact.